cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Bluebird Bio Inc
30 own
36 watching
Current Price
$6.65
$0.02
(0.3%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
551.15M
52-Week High
52-Week High
8.58
52-Week Low
52-Week Low
2.865
Average Volume
Average Volume
3.01M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization551.15M
icon52-Week High8.58
icon52-Week Low2.865
iconAverage Volume3.01M
iconDividend Yield--
iconP/E Ratio--
What does the Bluebird Bio Inc do?
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The company's lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Bluebird Bio Inc make?
News & Events about Bluebird Bio Inc.
Ticker Report
8days ago
bluebird bio, Inc. (NASDAQ:BLUE Get Rating) has earned a consensus rating of Hold from the ten ratings firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, six have given a hold rating and one has issued a buy ...
Business Wire
16days ago
bluebird bio, Inc. (Nasdaq: BLUE) (bluebird) today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.00 per share, before deducting underwriting discounts and commissions. bluebird also granted the underwriters a...
Business Wire
26days ago
bluebird bio, Inc. (Nasdaq: BLUE) (the Company) today announced updates to be presented at the 41st Annual J.P. Morgan Healthcare conference including commercial launch progress, 2023 program milestones and financial outlook. CEO Andrew Obenshain is scheduled to speak on Thursday, January 12 at...
Business Wire
29days ago
bluebird bio, Inc. (NASDAQ: BLUE) (bluebird bio or the Company) today announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher (PRV) for $95 million. bluebird bio was granted two PRVs upon the US Food and Drug Administration (FDA...
Business Wire
1month ago
bluebird bio, Inc. (Nasdaq: BLUE) today announced that Joseph Vittiglio, JD, has been appointed Chief Business and Legal Officer. Vittiglio brings more than 20 years of experience in the biopharmaceutical industry, with expertise in licensing, collaborations and mergers and acquisitions, financial...
Frequently Asked Questions
Frequently Asked Questions
What is Bluebird Bio Inc share price today?
plus_minus_icon
Can Indians buy Bluebird Bio Inc shares?
plus_minus_icon
How can I buy Bluebird Bio Inc shares from India?
plus_minus_icon
Can Fractional shares of Bluebird Bio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Bluebird Bio Inc stocks?
plus_minus_icon
What is today’s traded volume of Bluebird Bio Inc?
plus_minus_icon
What is today’s market capitalisation of Bluebird Bio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Bluebird Bio Inc?
plus_minus_icon
What percentage is Bluebird Bio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Bluebird Bio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$6.65
$0.02
(0.3%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00